Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. entrance

ENTRANCE SIGNED

Developing the iTOP kit: Empowering scientists with efficient intracellular delivery of biologicals in hard-to-manipulate cell types

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ENTRANCE project word cloud

Explore the words cloud of the ENTRANCE project. It provides you a very rough idea of what is the project "ENTRANCE" about.

extremely    team    lines    types    market    mammalian    sciences    immortalized    back    bv    stimulate    genetic    dna    instigate    manipulate    expand    journal    standard    scientific    difficult    investments    experiences    immense    innovative    marketing    primary    active    sharing    stem    2015    molecules    scientifically    move    therapeutic    ruo    fte    validated    human    16    drug    diseases    notoriously    underpin    bioactive    inside    entry    interactive    unprecedented    possibilities    merits    leader    technologies    ambition    2020    efficient    efficiency    wo2015028969    entrance    revolution    biomolecules    ntrans    create    tool    biomedical    kit    pace    forecasted    pipeline    unmet    proper    biologically    published    earn    significantly    patented    cell    cells    itop    rna    biomedically    sme    line    transfect    forum    community    accelerated    latter    combinations    models    proteins    developers    direct    generously    empowering    buzz   

Project "ENTRANCE" data sheet

The following table provides information about the project.

Coordinator		 NTRANS TECHNOLOGIES BV 

Organization address
address: UPPSALALAAN 8
city: UTRECHT
postcode: 3584 CT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Project website https://www.ntranstechnologies.com/entrance/
 Total cost 1˙514˙200 €
 EC max contribution 1˙514˙200 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NTRANS TECHNOLOGIES BV NL (UTRECHT) coordinator 1˙514˙200.00

Map

 Project objective

NTrans Technologies BV has developed iTOP; a novel and extremely effective method to deliver highly relevant bioactive molecules (including DNA, RNA, active proteins, and their combinations) into mammalian cells. This includes the efficient delivery of such molecules inside the most biologically and biomedically relevant cell types (e.g. human primary and stem cells), which are notoriously difficult to manipulate. iTOP technology has been scientifically validated (published in the top scientific journal Cell in 2015) and patented (WO2015028969).

iTOP addresses the unmet need of researchers and drug developers to be able to transfect a range of biomolecules into biologically relevant cell models; in particular to study genetic diseases and to underpin results obtained with standard immortalized cell lines.

The ENTRANCE project includes the necessary steps towards market entry of the iTOP research-use-only (RUO) kit: The development of (i) an iTOP RUO kit and (ii) an iTOP on-line community as innovative marketing tool that will support proper use and stimulate efficient application of the technology. The ENTRANCE project will thus provide the scientific community access to the novel iTOP tool, facilitate direct access of iTOP kit users to the NTrans support team, and enable sharing of user experiences via an iTOP interactive forum.

ENTRANCE will instigate a revolution in biomedical sciences by empowering both researchers and drug developers to manipulate the most relevant cell types with unprecedented efficiency. This will allow the field to move forward at a significantly accelerated pace.

The iTOP RUO kit will generously earn back the investments within 4 years, and help to create a buzz around the merits and possibilities of the technology. The latter is of immense value to the SME forecasted to support 16 FTE by 2020, with the ambition to expand its product pipeline and become leader in technologies for delivery of therapeutic biomolecules into primary cells.

 Deliverables

List of deliverables.
3.4b iTOP community platform completed Websites, patent fillings, videos etc. 2020-03-24 11:33:03
1.5b First lot of sample kit produced Demonstrators, pilots, prototypes 2020-02-27 15:22:05
1.3 Digital user manuals completed Documents, reports 2020-02-27 15:21:52
3.5b Final version of the DMP Documents, reports 2019-07-30 13:59:42
3.1b Report of the Mid-Term event Documents, reports 2019-05-31 11:55:55
3.3a Dedicated web pages for ENTRANCE Websites, patent fillings, videos etc. 2019-05-31 11:55:51
3.1a Report of the Kick-off Event Documents, reports 2019-05-31 11:55:52
3.5a First version of DMP Documents, reports 2019-05-31 11:56:04

Take a look to the deliverables list in detail:  detailed list of ENTRANCE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENTRANCE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ENTRANCE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More